| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | GMP, ISO 9001, USP, BP |
| Suitable for: | Elderly, Adult, Animal |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Pharmaceutical Grade High quality 99% powder Liraglutide price cas 204656-20-2 Raw powder low price Liraglutide
|
Product Name
|
Liraglutide Powder 99% CAS 204656-20-2 |
|
Appearance
|
white powder |
|
Assay
|
99%min, 98.0% --101.0% |
|
Test
|
HPLC
|
|
Certificate
|
ISO 9001
|
|
CAS
|
204656-20-2 |
| MF | C172H265N43O51 |
| Storage Temperature |
Cool Dry Place
|
|
TEM
|
SPECIFICATION
|
METHOD REFERENCE
|
|
Appearance
|
white powder
|
Visual
|
|
Ammonium
|
≤200ppm
|
USPmonograph
|
|
Chloride
|
≤200ppm
|
USP35<221>
|
|
Sulfate
|
≤300ppm
|
USP35<221>
|
|
Iron
|
≤10ppm
|
USP35<241>
|
|
Arsenic
|
≤2ppm
|
USP35<211>
|
|
Heavy metals
|
≤10ppm
|
USP35<231>Method I
|
|
Loss on drying(3h at 105 ºC)
|
≤0.5%
|
USP35<731>
|
|
Residue on Ignition
|
≤0.1%
|
USP35<281>
|
|
Total impurities
|
≤2.0%
|
USP monograph
|
|
Assay(dry basis)
|
98.0% to 101.0%
|
USP monograph
|
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates Insuln secretion.
Function
1.It acts in a glucose-dependent manner, meaning it will stimulate Insuln secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
2.It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3.It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
4.It lowers blood triglyceride levels.
Application
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
| Product Name | CAS No. | Product Name | CAS No. |
| Lufenuron | 103055-07-8 | Toltrazuril | 69004-03-1 |
| Nitenpyram | 120738-89-8 | Praziquantel/Biltricide | 55268-74-1 |
| Fenbendazole | 43210-67-9 | Tetramisole Hcl | 5086-74-8 |
| Levamisole | 14769-73-4 | Ponazuril | 9004-4-2 |
| Diclazuril | 101831-37-2 | Florfenicol | 73231-34-2 |
| Ivermectin | 70288-86-7 | Enrofloxacin Hcl | 112732-17-9 |
| Albendazole | 54965-21-8 | Mebendazole | 31431-39-7 |
Xi'an Biohorlden Industry&Trade Co.,Ltd is a national key high-tech enterprise,which mainly specializes in the R&D, operation and production of pharmaceuticals,and intermediates.Our company is situated in E&T development zone,xi'an city shaanxi,it is easy of access. Our company has independent R&D center,raw material synthesis workshop, has advanced quality instruments and equipmentm,several product patents there are 15 experts in our research team.We insist in innovation and produce high quality products.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}